CSBio CSBio

X
[{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Premas Biotech"},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cipla"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: SIGA Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike, Envelope, and Membrane (M) that they have selected for their vaccine candidate.

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY